九福来

Jufeel launched the listing to NASDAQ in America

Jufeel launched the listing to NASDAQ in America

  Recently, Kaifeng Jufeel Biological Technology Co., Ltd collaborates with J. Streicher of America held merger and acquisition signing ceremony at Four Seasons Hotel Beijing. Chairman of Jufeel, Mr. Zhang Rongxuan and the president of J. Streicher, Mr. Priebe Jeffrey James Mayo, and president of Asia-Pacific region, Ms. Angelina Qin Rao, general manager Mr. Palum Richard Ryan attended the ceremony.

  The merger and acquisition has attracted hundreds of local and overseas enterprises, including the management of US listed companies, law firms, accounting firms, senior experts of overseas investment. The famous investor Gu Choujun, former general manager of the Carlyle Group (US), CEO of Infinity Group (Israel) Hubin, chairman of Zhongkerongchuang (Beijing) Mr. Xue Wentao, chairman of Yunjitianxia Mr. Zhang Yu etc participated the ceremony.

  The spoke person of Jufeel stated that, the signing ceremony signals the start-up of the listing in America, the reputed in aloe vera industry, Jufeel will be probably listed in NASDAQ, becoming the first Chinese aloe vera enterprise in US stock market. By then, Jufeel will raise more capital to intensify the investment to aloe vera industry, and forge ahead towards the world-class aloe vera biotechnology hi-tech company.

  Chairman of Jufeel, Mr. Zhang Rongxuan expressed that, Jufeel has been preparing for listing for years. This year, Jufeel will further optimize and perfect the agent channels in more than 200 cities in China, and witness the remarkable increase of aloe vera business scale. Prior to the end of 2016, we are confident to achieve the goal of relative higher increment of net profit. Jufeel is guided by the principle of creating better life, will stride forward to the world-class enterprise steadily in aloe vera life science and technology field.

Chairman of Jufeel, Mr. Zhang Rongxuan answers questions with respect to the listing

  During the interview, the president of J. Streicher Mr. Priebe Jeffrey James Mayo stated that, there are more than 200 biological technology companies listed in NYSE. Comparing with those listed companies, Jufeel has an international vision and unique core value and competiveness. J. Streicher will escort the development of Jufeel and do his best to make differences. Mr. Priebe Jeffrey James Mayo also remarked optimistically that the stock market value would exceed billions of CNY in the next three months.

  The managing director of J. Streicher, Mr. Plum Richard Ryan said that, Jufeel’s advanced technologies will be extensively applied in the medical health field in the future. As the listing sponsor, J. Streicher has obtained the suitable target for this merger and acquisition. In accordance with SEC listing review procedure, J. Streicher will assign top four accounting firm and experienced law firms to enter Jufeel headquarters following the ceremony, to secure the prompt listing of Jufeel. J. Streicher will not only be the listing sponsor, but invest more funds in phases to become Jufeel’s stake holder, in collaboration with Jufeel, building Jufeel to be world renowned company in aloe vera life science and technology field.

President of J. Streicher, Mr. Priebe Jeffrey James Mayo delivers speech

  J. Streicher has a history of 106 year in New York, and it is a diversified financial company. So far, J. Streicher has successfully completed the listing of Disney, KLM Royal Dutch Airlines, Harley Davidson, and Sunoco etc.

  Kaifeng Jufeel Biological Technology Co., Ltd was established in 2011, which is dedicated in aloe vera organic planting, raw materials processing, aloe vera bio extraction, anti-HIV drugs, anti-tumor drugs development etc, has developed into national hi-tech enterprise with aloe vera comprehensive industry as its core. As the discoverer and manufacturer of PMAS-Anti-aging technology of aloe vera living cells and purification technology of bio-Immunoglycan, it is as well the well known major organic planter and research organization on aloe vera related drugs.

  As the outstanding private company, Jufeel possesses the aloe vera extraction and purification technology, which is authoritative in the industry, and supplies the majority of high-end raw materials in China. The influence has been widely recognized. Jufeel products have been certified by EU organic planting and processing, NOP organic planting and processing, FDA food security certificate, JAS organic planting and processing, European food security certificate PAS220 initiated by Holland, European food security certificate FSSC2200 initiated by UK, Jewish food security certificate, and IASC certificate. Furthermore, our products have passed China organic planting and processing, ISO 9002 series management certificate; the products are well received in America, Italy, Germany, Spain, New Zealand, Australia, Japan, South Korea, Malaysia etc; Jufeel also partners with a number of world leading companies in the supply of raw materials.

Managing director of J.Streicher, Mr. Plum Richard Ryan delivers speech.

  Jufeel attaches great importance to aloe vera biological technology, and has completed a series of aloe vera industry chain construction, 2000 mu of organic aloe vera planting in Hainan, raw materials extraction center in Haikou, manufacturing base, national marketing center, PMAS manufacturing base, Jufeel Changzhou University joint research center etc.

  Mr. Zhang Rongxuan, the chief scientist of Jufeel, introduced Aloe Vera from America to Hainan province in 1999, and named it “Kulasuoluhui”, to date, the company has been in the industry for more than 17 years. For years of unwavering pursuit and research, Mr. Zhang Rongxuan and his team succeeded in extracting PMAS, J01, J02, and J011, J031 etc, which contained the ingredients to treat HIV, tumor, and anti-aging. The research has been awarded a dozen of patents, part of the patents have been reviewed by PCT, and leading in the world.

  In light of the significant efficacy of biologic agent, on May 20, 2016, PMAS developed by Kaifeng Jufeel Biological Technology Co., Ltd and PMAS Biological Technology (Tanzania) Co., Ltd has been approved by TFDA as a supplementary drug against HIV after almost three years. The approval allows PMAS to be distributed in the pharmacies and hospitals in East Africa Unity region, covering in six East African Countries with the population of more than 27 million.

Group photos of the management members of Jufeel and J. Streicher

  PMAS agent contains acemannan extracted from aloe vera. It will rapidly repair of human immunodeficiency, and rebuild human immune system, to achieve the repression of HIV virus replication. Acemannan can rapidly produce highly effective antiviral and antineoplastic activities in vivo, so it can also be used as a substitute for cancer inhibitors in chemotherapy.

Back to list